Atlas Trials

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Clinical trial NCT01500278 · COMPLETED

Trial details

NCT number
NCT01500278
Sponsor
UCB Pharma SA
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Rheumatoid Arthritis
Start date
2011-12-01
Primary completion
2015-11-01
Enrollment
915

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.